PRIVIA HEALTH GROUP INC (PRVA) Stock Fundamental Analysis
NASDAQ:PRVA - US74276R1023 - Common Stock
23.04 USD
+1.23 (+5.64%)
23.04 USD
0 (0%)
Taking everything into account, PRVA scores 4 out of 10 in our fundamental rating. PRVA was compared to 102 industry peers in the Health Care Providers & Services industry. While PRVA seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, PRVA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year PRVA was profitable.
In the past year PRVA had a positive cash flow from operations.
In multiple years PRVA reported negative net income over the last 5 years.
In the past 5 years PRVA always reported a positive cash flow from operatings.
1.2 Ratios
PRVA has a Return On Assets (1.17%) which is in line with its industry peers.
PRVA has a Return On Equity (2.17%) which is in line with its industry peers.
PRVA has a Return On Invested Capital (1.78%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.17% | ||
| ROE | 2.17% | ||
| ROIC | 1.78% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRVA has a Profit Margin (0.78%) which is comparable to the rest of the industry.
PRVA's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 1.03%, PRVA is in line with its industry, outperforming 42.16% of the companies in the same industry.
PRVA's Operating Margin has declined in the last couple of years.
PRVA has a worse Gross Margin (9.96%) than 72.55% of its industry peers.
PRVA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.03% | ||
| PM (TTM) | 0.78% | ||
| GM | 9.96% |
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PRVA is destroying value.
PRVA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PRVA has more shares outstanding
PRVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 4.56 indicates that PRVA is not in any danger for bankruptcy at the moment.
The Altman-Z score of PRVA (4.56) is better than 78.43% of its industry peers.
There is no outstanding debt for PRVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.56 |
ROIC/WACC0.2
WACC8.87%
2.3 Liquidity
PRVA has a Current Ratio of 1.65. This is a normal value and indicates that PRVA is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of PRVA (1.65) is comparable to the rest of the industry.
A Quick Ratio of 1.65 indicates that PRVA should not have too much problems paying its short term obligations.
PRVA's Quick ratio of 1.65 is in line compared to the rest of the industry. PRVA outperforms 58.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.65 |
3. Growth
3.1 Past
PRVA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.33%.
Measured over the past 5 years, PRVA shows a small growth in Earnings Per Share. The EPS has been growing by 7.43% on average per year.
Looking at the last year, PRVA shows a quite strong growth in Revenue. The Revenue has grown by 12.05% in the last year.
Measured over the past years, PRVA shows a quite strong growth in Revenue. The Revenue has been growing by 17.17% on average per year.
EPS 1Y (TTM)-8.33%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%-33.33%
Revenue 1Y (TTM)12.05%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%18.53%
3.2 Future
PRVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 59.10% yearly.
PRVA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.19% yearly.
EPS Next Y50.02%
EPS Next 2Y72.07%
EPS Next 3Y59.1%
EPS Next 5YN/A
Revenue Next Year14.8%
Revenue Next 2Y12.52%
Revenue Next 3Y12.82%
Revenue Next 5Y2.19%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 209.45, which means the current valuation is very expensive for PRVA.
The rest of the industry has a similar Price/Earnings ratio as PRVA.
When comparing the Price/Earnings ratio of PRVA to the average of the S&P500 Index (27.08), we can say PRVA is valued expensively.
Based on the Price/Forward Earnings ratio of 70.75, the valuation of PRVA can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PRVA is on the same level as its industry peers.
The average S&P500 Price/Forward Earnings ratio is at 22.72. PRVA is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 209.45 | ||
| Fwd PE | 70.75 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PRVA indicates a slightly more expensive valuation: PRVA is more expensive than 60.78% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PRVA is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.19 | ||
| EV/EBITDA | 87.91 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PRVA does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as PRVA's earnings are expected to grow with 59.10% in the coming years.
PEG (NY)4.19
PEG (5Y)28.17
EPS Next 2Y72.07%
EPS Next 3Y59.1%
5. Dividend
5.1 Amount
PRVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
23.04
+1.23 (+5.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners99.78%
Inst Owner Change-2.09%
Ins Owners1.87%
Ins Owner Change3.64%
Market Cap2.83B
Analysts84.29
Price Target30.96 (34.38%)
Short Float %2.85%
Short Ratio3.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-49.4%
Min EPS beat(2)-60.96%
Max EPS beat(2)-37.83%
EPS beat(4)0
Avg EPS beat(4)-44.58%
Min EPS beat(4)-60.96%
Max EPS beat(4)-37.83%
EPS beat(8)0
Avg EPS beat(8)-41.13%
EPS beat(12)4
Avg EPS beat(12)50.02%
EPS beat(16)7
Avg EPS beat(16)58.25%
Revenue beat(2)2
Avg Revenue beat(2)3.24%
Min Revenue beat(2)0.75%
Max Revenue beat(2)5.73%
Revenue beat(4)4
Avg Revenue beat(4)3.97%
Min Revenue beat(4)0.75%
Max Revenue beat(4)7.92%
Revenue beat(8)8
Avg Revenue beat(8)3.27%
Revenue beat(12)9
Avg Revenue beat(12)-4.22%
Revenue beat(16)10
Avg Revenue beat(16)-9.82%
PT rev (1m)-0.82%
PT rev (3m)2.53%
EPS NQ rev (1m)-20.38%
EPS NQ rev (3m)-36.64%
EPS NY rev (1m)-21.35%
EPS NY rev (3m)-21.89%
Revenue NQ rev (1m)-0.82%
Revenue NQ rev (3m)-1.72%
Revenue NY rev (1m)2.72%
Revenue NY rev (3m)2.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 209.45 | ||
| Fwd PE | 70.75 | ||
| P/S | 1.49 | ||
| P/FCF | 29.19 | ||
| P/OCF | 30.78 | ||
| P/B | 4.14 | ||
| P/tB | 8.3 | ||
| EV/EBITDA | 87.91 |
EPS(TTM)0.11
EY0.48%
EPS(NY)0.33
Fwd EY1.41%
FCF(TTM)0.79
FCFY3.43%
OCF(TTM)0.75
OCFY3.25%
SpS15.48
BVpS5.56
TBVpS2.77
PEG (NY)4.19
PEG (5Y)28.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.17% | ||
| ROE | 2.17% | ||
| ROCE | 2.66% | ||
| ROIC | 1.78% | ||
| ROICexc | 3.77% | ||
| ROICexgc | 251.71% | ||
| OM | 1.03% | ||
| PM (TTM) | 0.78% | ||
| GM | 9.96% | ||
| FCFM | 5.1% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5Y-10.22%
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
F-Score5
Asset Turnover1.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 77.53 | ||
| Cash Conversion | 331.3% | ||
| Profit Quality | 652.71% | ||
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.65 | ||
| Altman-Z | 4.56 |
F-Score5
WACC8.87%
ROIC/WACC0.2
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.33%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%-33.33%
EPS Next Y50.02%
EPS Next 2Y72.07%
EPS Next 3Y59.1%
EPS Next 5YN/A
Revenue 1Y (TTM)12.05%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%18.53%
Revenue Next Year14.8%
Revenue Next 2Y12.52%
Revenue Next 3Y12.82%
Revenue Next 5Y2.19%
EBIT growth 1Y52.75%
EBIT growth 3YN/A
EBIT growth 5Y1.07%
EBIT Next Year514.99%
EBIT Next 3Y106.08%
EBIT Next 5Y64.83%
FCF growth 1Y145.73%
FCF growth 3Y26.09%
FCF growth 5Y42.42%
OCF growth 1Y132.44%
OCF growth 3Y25.67%
OCF growth 5Y35.01%